<DOC>
	<DOCNO>NCT02543866</DOCNO>
	<brief_summary>This protocol evaluate fecal microbiota transplantation ( FMT ) strategy eradicate intestinal colonization extended-spectrum resistant ( ESC-R ) Enterobacteriaceae pediatric patient . FMT perform subject history least one infection due ESC-R Enterobacteriaceae . This protocol aim determine feasibility , safety , tolerability , potential efficacy FMT pediatric patient history ESC-R Enterobacteriaceae .</brief_summary>
	<brief_title>Fecal Microbiota Transplantation Strategy Eradicate Resistant Organisms</brief_title>
	<detailed_description>This prospective pilot study fecal microbiota transplantation pediatric patient history ESC-R Enterobacteriaceae . Subjects meet inclusion/exclusion criterion provide write , informed consent undergo screen study provide pre-FMT stool sample confirm intestinal carriage ESC-R Enterobacteriaceae . The FMT administer nasogastric tube outpatient set trained personnel . The subject monitor potential adverse event , recurrence MDRO infection , infection may relate FMT , worsen exist comorbidities development new comorbidities 12 month post-FMT option participate long-term follow-up 5 year post-FMT . Patients provide stool sample 2 day , 2 week , 4 week , 8 week , 6 month , 12 month post-FMT . These sample test ESC-R Enterobacteriaceae .</detailed_description>
	<criteria>1 . Children adolescents 7 21 year age . 2 . A history least one infection due ESCR Enterobacteriaceae . ESCR isolates define nonsusceptible ceftriaxone , cefotaxime , ceftazidime . 3 . Parent/guardian participant must able attend baseline followup study visit . 4 . Subject must willing able provide write informed consent assent ( appropriate age ) . 1 . Patients history malignancy immunocompromised state ( e.g . absolute neutrophil count outside normal range ) induce disease therapy exclude . 2 . Patients past current use systemic immunosuppressive agent exclude . Receipt nonsystemic agent inhale , nasal , topical steroid immunemodulating agent allow . 3 . Lack intestinal carriage ESCR Enterobacteriaceae ( negative selective stool culture ESCR Enterobacteriaceae ) . 4 . Allergy hypersensitivity omeprazole polyethylene glycol . 5 . Pregnancy . 6 . Current history frequent ( &gt; 1 per week ) vomiting . 7 . Active inflammatory gastrointestinal disease , inflammatory bowel disease 8 . Active mucositis acute graft versus host disease gastrointestinal tract 9 . Concurrent abdominal radiation therapy . 10 . Inability tolerate nasogastric tube placement contraindication NG tube place . 11 . Presence ventriculoperitoneal shunt intrabdominal device , receipt renal dialysis , presence ascites , conditions/devices would increase risk peritonitis . 12 . Bleeding diatheses 13 . Patients current active ESCR Enterobacteriaceae infection yet complete antibiotic treatment exclude treatment complete</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>